U.S. markets closed
  • S&P Futures

    3,293.25
    +6.00 (+0.18%)
     
  • Dow Futures

    27,104.00
    +61.00 (+0.23%)
     
  • Nasdaq Futures

    11,146.25
    +9.75 (+0.09%)
     
  • Russell 2000 Futures

    1,473.60
    +6.40 (+0.44%)
     
  • Crude Oil

    39.98
    -0.27 (-0.67%)
     
  • Gold

    1,863.30
    -3.00 (-0.16%)
     
  • Silver

    23.03
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1637
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • Vix

    26.38
    -2.13 (-7.47%)
     
  • GBP/USD

    1.2767
    +0.0023 (+0.18%)
     
  • USD/JPY

    105.5010
    -0.0450 (-0.04%)
     
  • BTC-USD

    10,861.69
    +82.88 (+0.77%)
     
  • CMC Crypto 200

    223.55
    +5.72 (+2.63%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,362.01
    +157.39 (+0.68%)
     

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Flexion Therapeutics, Inc.

BURLINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 13,940 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of September 1, 2020. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the shares vesting on each annual anniversary of the applicable vesting commencement date, subject to the new employee’s continued service relationship with the Company.  

The restricted stock units are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com.

Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com